The global market for biomarkers is expected to grow to $12.8 billion by 2012, up from $5.6 billion today. That represents a compound average annual growth rate of 18 percent, according to BCC Research, the Wellesley, Mass-based research firm that made the forecast. Pre-clinical studies of drug development and diagnostics research applications accounted for nearly half of the total in 2007. Public-private partnerships and the U.S. FDA's Critical Path Initiative are fostering the adoption of molecular markers and the use of imaging biomarkers as potential surrogate end-points in clinical trials. The use of biomarkers in oncology therapeutics is likely to be one of the foremost priorities followed by cardiovascular and CNS applications in the next three to seven years.


GLOBAL MARKET FOR BIOMARKERS SLATED FOR HIGH GROWTH THROUGH 2012 

 

The global market for biomarkers is expected to grow to $12.8 billion by 2012, up from $5.6 billion today. That represents a compound average annual growth rate of 18 percent, according to BCC Research, the Wellesley, Mass-based research firm in a report 2007. This is expected to increase to over $12.8 billion by 2012, a compound average annual growth rate (CAGR) of 18%. The firm said pre-clinical studies of drug development and diagnostics research applications accounted for nearly half of the total in 2007. The firm said public-private partnerships and the U.S. FDA's Critical Path Initiative are fostering the adoption of molecular markers and the use of imaging biomarkers as potential surrogate end-points in clinical trials. The use of biomarkers in oncology therapeutics is likely to be one of the foremost priorities followed by cardiovascular and CNS applications in the next 3 to 7 years.


Revenue forecast for global biomarkers market by segments, through 2012 in millions